An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.

[1]  Selective COX-2 inhibitors: where do we go from here? , 2008, The Lancet.

[2]  D. DeMets,et al.  Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial , 2008, The Lancet.

[3]  F. Chan,et al.  Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents , 2008, The American Journal of Gastroenterology.

[4]  Jean-Yves Reginster,et al.  Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial , 2008, Journal of hypertension.

[5]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. , 2008, Osteoarthritis and cartilage.

[6]  F. Gengo,et al.  Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis , 2008, Journal of clinical pharmacology.

[7]  V. Strand.  Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? , 2007, The Lancet.

[8]  P. Loehrer.  Celecoxib for the Prevention of Colorectal Adenomatous Polyps , 2008 .

[9]  V. Fuster,et al.  Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib , 2007, Annals of the rheumatic diseases.

[10]  P. Gorelick,et al.  Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. , 2007, The American journal of cardiology.

[11]  C. Bombardier,et al.  Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2006, The Lancet.

[12]  B. Martin,et al.  Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) , 2006, PLoS clinical trials.

[13]  S. Nissen,et al.  ADAPT: The Wrong Way to Stop a Clinical Trial , 2006, PLoS clinical trials.

[14]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[15]  S. Solomon,et al.  Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.

[16]  R. de Caterina,et al.  Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease , 2006, Clinical pharmacology and therapeutics.

[17]  R. Huupponen,et al.  NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. , 2006, European heart journal.

[18]  P. Raina,et al.  Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. , 2006, The American journal of medicine.

[19]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[20]  M. Hochberg,et al.  P96 EFFECT OF OVER-THE-COUNTER DOSES OF NAPROXEN SODIUM ON INHIBITION OF PLATELET CYCLOOXYGENASE-1 IN HEALTHY VOLUNTEERS , 2006 .

[21]  R. Chou,et al.  Comparative Effectiveness and Safety of Analgesics for Osteoarthritis , 2006 .

[22]  L. G. García Rodríguez,et al.  Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population , 2005, BMC medicine.

[23]  Joseph Loscalzo,et al.  Cyclooxygenase inhibition and cardiovascular risk. , 2005, Circulation.

[24]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[25]  H. Sørensen,et al.  Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. , 2005, Archives of internal medicine.

[26]  E. Ricciotti,et al.  Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.

[27]  D. Graham,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study , 2005 .

[28]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[29]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[30]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[31]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[32]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[33]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[34]  C. Patrono,et al.  Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects , 2004, Circulation.

[35]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[36]  T. Macdonald,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[37]  J. Eikelboom,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[38]  W. White,et al.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. , 2002, The American journal of cardiology.

[39]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors☆ , 2002 .

[40]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[41]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[42]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[43]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[44]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[45]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.